Introduction {#Sec1}
============

The genus *Vinca* (Apocynaceae), distributed through Europe, Northwest Africa, and South-west Asia, represents a group of species which are rich in indole alkaloids of diverse structural patterns, many of which are of considerable therapeutic value \[[@CR1]--[@CR4]\]. *Vinca major* has been used for centuries as a folk remedy in the treatment of menorrhagia and diabetes, and as an abortifacient and vulnerary \[[@CR5]\]. Delphinidin glycosides have been isolated from the flowers of *V. major* \[[@CR6]\] while chlorogenic acid, robinin, and flavonol triglycoside are extracted from its leaves \[[@CR7]\]. In addition, a number of indole alkaloids are also reported from this plant \[[@CR8]--[@CR13]\]. Previously, we isolated non-alkaloid constituents \[[@CR14]\] as well as indole alkaloids \[[@CR15]\] from *V. major* cultivated in Kunming. In our ongoing search for alkaloids from this plant growing in different habitats, we carried out the phytochemical investigation of the aerial parts of *V. major* in Pakistan, and then isolated three new pyridine alkaloids, named as (--)-vincapyridines A--C (**1**--**3**) trivially (Fig. [1](#Fig1){ref-type="fig"}). The structures of new alkaloids were elucidated by means of spectroscopic methods. The new alkaloids were evaluated for their cytotoxicity against human glioma initiating cell lines (GITC-3^\#^ and GITC-18^\#^), glioblastoma cell lines (U-87MG and T98G), and lung cancer cell line A-549 using the reported MTS assay with DMSO as the control group. Unfortunately, none of these compounds exhibited significant cytotoxicity at 20 μg/mL concentration. Herein, we report the isolation, structural elucidation of these compounds.Fig. 1Structures of compounds **1**--**5**

Results and Discussion {#Sec2}
======================

The molecular formula of **1** was determined to be C~13~H~17~NO~4~, by a quasi-molecular ion peak at *m/z* 252.1222 \[M+H\]^+^ (calcd for C~13~H~18~NO~4~, 252.1230) in the positive HRESIMS. Its IR spectrum revealed a characteristic absorption band at 1724 (C=O). The ^1^H and ^13^C NMR spectral data of **1** (Table [1](#Tab1){ref-type="table"}), assumed that **1** was a tri-substituents pyridine derivative with two typical downfield protons \[*δ* ~H~ 8.89 (s) and 8.53 (s)\] assigned to be pyridine aromatic protons \[[@CR16]\]. In HMBC spectrum of **1**, correlations of pyridine protons *δ* ~C~ 8.53 (s) with substituents aromatic carbons at *δ* ~C~ 146.3 (C-7), 137.6 (C-2), and oxymethine at *δ* ~C~ 71.3 (C-3), indicated substituents pattern (Fig. [2](#Fig2){ref-type="fig"}). Moreover, HMBC correlations of *δ* ~H~ 4.88 (H-5) with *δ* ~C~ 71.3 (C-3) and *δ* ~C~ 146.3 (C-7) established a substituents pyranose ring fused to the pyridine ring (Fig. [2](#Fig2){ref-type="fig"}). Besides, HMBC correlations of *δ* ~H~ 1.64 (3H, d, --CH~3~) with *δ* ~C~ 71.3 (C-3), and of *δ* ~H~ 3.99 and 3.62 (2H, --OC[H]{.ul} ~2~CH~3~) with *δ* ~C~ 99.6 (C-5), placed a methyl at C-6 and oxyethyl group at C-5, respectively, which was further supported by the correlations of *δ* ~H~ 3.37/4.88, 3.99/1.24, and 5.02/1.64, in its ^1^H--^1^H COSY spectrum (Fig. [2](#Fig2){ref-type="fig"}). Finally, the HMBC correlations of *δ* ~H~ 8.89 (s) and 3.92 (--OC[H]{.ul} ~3~) with *δ* ~C~ 167.2 (--[C]{.ul}OOCH~3~) positioned the methyl formate group at C-8. In ROESY spectrum of **1**, NOE correlation between *δ* ~H~ 4.88 (H-5) and 1.64 (H-4) revealed two protons to be co-facial (Fig. [2](#Fig2){ref-type="fig"}), which indicated its relative configuration.Table 1^1^H and ^13^C NMR spectroscopic data of **1**--**3** (*δ* in ppm, *J* in Hz)Position**123***δ* ~H~^a^*δ* ~C~^b^*δ* ~H~^a^*δ* ~C~^b^*δ* ~H~^a^*δ* ~C~^b^18.53 (s)149.88.51 (s)149.58.33 (br. s)146.02137.6137.5137.235.02 (q, 6.4)71.54.98 (q, 6.6)64.54.94 (q, 6.6)64.741.64 (d, 6.4)21.91.58 (d, 6.6)21.41.57 (d, 6.6)21.054.88 (dd, 3.2, 8.2)99.65.07 (dd, 1.2, 4.6)97.75.17 (dd, 1.4, 4.6)96.763.37 (dd, 3.2, 18.2)\
3.07 (dd, 8.2, 18.2)35.03.35 (dd, 4.6, 18.6)\
3.21 (br. d, 18.6)33.23.14 (dd, 4.6, 17.3)\
2.75 (d, 17.3)34.37146.3144.7143.58126.9126.67.18 (d, 5.2)125.598.89 (s)150.28.88 (s)150.18.29 (br. d, 5.2)147.8--O[CH]{.ul} ~2~CH~3~3.99 (dq, 7.1, 9.4)\
3.62 (dq, 7.1, 9.4)65.43.85 (dq, 7.1, 9.7)\
3.58 (dq, 7.1, 9.7)64.3--OCH~2~ [CH]{.ul} ~3~1.24 (t, 7.1)15.71.19 (t, 7.1)15.5--[C]{.ul}OOCH~3~167.2167.3--COO[CH]{.ul} ~3~3.92 (s)52.93.92 (s)52.9--OCH~3~3.44 (s)55.6^a^Recorded at 600 MHz in CD~3~OD^b^Recorded at 150 MHz in CD~3~OD Fig. 2Selective HMBC (→), ^1^H--^1^H COSY (−), and ROESY (↔) correlations for **1**--**3**

The molecular formula of **2** was established as C~12~H~15~NO~4~ by a quasi-molecular ion peak in the HRESIMS at *m*/*z* 238.1072 \[M+H\]^+^ (calcd for C~12~H~16~NO~4~, 238.1074). The ^1^H and ^13^C NMR spectral data of **2** were similar to those of **1**, except for a methoxyl group connected to C-5 in **2** instead of the ethoxyl group in **1**, which was consistent with its molecular formula, and further supported by HMBC correlation. Compound **2** shared same relative configurations with **1**, supported by NOE correlation between H-5 and H-4 (Fig. [2](#Fig2){ref-type="fig"}).

Its molecular formula of **3** was deduced to be C~11~H~15~NO~2~ on the basis of HRESIMS quasi-molecular ion peak at *m/z* 194.1172 \[M+H\]^+^ (calcd for C~11~H~16~NO~2~, 194.1176) and ^13^C NMR data (Table [1](#Tab1){ref-type="table"}). Signals for methyl formate group at C-8 in the ^1^H and ^13^C NMR spectra of **1** were absent in those of **3**,and corresponding *δ* ~H~ 7.18 (d, 5.2, H-8) and *δ* ~C~ 125.5 (d, C-8) were appeared in the ^1^H and ^13^C NMR spectra of **3**. Other parts of **3** were identical to those of **1**, supported by its HMBC and ROSEY spectra (Fig. [2](#Fig2){ref-type="fig"}).

The optical rotation of **1**--**3** with same negative sign, supposed their same absolute configuration. However, the specific rotation values of **1**--**3** were obviously different, which indicated that substituents at C-8 and 5 contributed to specific rotation significantly. In compound **1**, to avoid steric hindrance between --COOCH~3~ and --OCH~2~CH~3~ (Fig. [3](#Fig3){ref-type="fig"}), the dihedral angle between H-6 and H-5 were changed, resulting in a large coupling constants (*J* = 8.4 Hz) for H-6/H-5 in its ^1^H NMR spectrum, which were different from those of two other compounds. Meanwhile, the deformed substituent pyran forward the hemiacetal proton (H-5) to the shield area of pyridine ring (Fig. [3](#Fig3){ref-type="fig"}), which caused the up-field chemical shift of H-5 (*δ* ~H~ 4.88) in **1,** comparison of those in **2** (*δ* ~H~ 5.07) and **3** (*δ* ~H~ 5.17). It is the first report of pyridine type alkaloids from genus *Vinca*. Besides, known indole alkaloids nauclefine (**4**) \[[@CR17], [@CR18]\] and vincamajoreine (**5**) \[[@CR19]\] were also isolated.Fig. 3Conformation change of compound **1** indicated by molecular model

Experimental Section {#Sec3}
====================

Plant Material {#Sec4}
--------------

The aerial parts of *V. major* were collected from Oghi, Mansehra, KPK, Pakistan in June, 2015 and identified by one of us (A. Khan). A voucher specimen (No. Khan_20150601) has been deposited in the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, China.

General Experimental Procedures {#Sec5}
-------------------------------

Optical rotations were performed on a P-1020 polarimeter. IR spectra were measured on a Bruker FT-IR Tensor 27 spectrometer with KBr pellets. UV spectra were obtained on Shimadzu UV-2401A spectrometer. 1D and 2D-NMR spectra were recorded on Bruker AV-600 MHz spectrometer. Coupling constants were expressed in Hertz and chemical shifts were given on a ppm scale with tetramethylsilane as an internal standard. HRESIMS were recorded on an API QSTAR Pulsar 1 spectrometer. Column chromatography (CC) was performed on silica gel (200--300 mesh, Qingdao Marine Chemical Ltd., Qingdao, People's Republic of China), Sephadex LH-20 (Pharmacia Fine Chemical Co., Ltd., Sweden), and MCI-gel CHP 20P (75--100 μm, Mitsubishi Chemical Co., Ltd). Thin-layer chromatography (TLC) was carried out on pre-coated silica gel plates (Qingdao Marine Chemical Co., Ltd.) with CHCl~3~/MeOH (15:1, 4:1, v/v) as developing solvents and spots were visualized by Dragendorff's reagent. High performance liquid chromatography (HPLC) was performed using Waters 600 pump with semi-preparative C~18~ columns (150 × 9.4).

Extraction and Isolation {#Sec6}
------------------------

The air-dried and powdered aerial parts of *V. major* (8 kg) were extracted with 80% aqueous MeOH (80 L × 3) at room temperature. After removal of the organic solvent under reduced pressure, the residue was dissolved in 0.3% aqueous hydrochloric acid (v/v). The solution was subsequently basified to pH 9--10 using aqueous ammonia, and then extracted with EtOAc (3 L × 4) to give an alkaloidal extract (34.3 g). The extract was applied to a silica gel column (CHCl~3~/MeOH, 1:0--0:1) to afford nine fractions (Fr. A-I). Fr. B (2.5 g) was subjected to silica gel column chromatography (CC) using a petroleum ether/acetone gradient eluent (10:1--9:1) to afford sub-fractions (Fr. 1--5). Fr. 4 (200 mg) was further purified on MCI-gel CHP 20P column using a MeOH/H~2~O gradient eluent (1:4--1:0) and on a semi-preparative C~18~ HPLC column with a gradient of MeOH/H~2~O (50:50--90:10) to yield vincamajoreine (**5**) (6 mg). Fr. H (5 g) was subjected to silica gel CC (CHCl~3~/MeOH, 9:1--0:1) to afford sub-fractions (Fr. 5--10). Fr. 5 (1200 mg) was further separated on MCI-gel CHP 20P column to yield nauclefine (**4**) (15 mg). Fr. 8 (800 mg) was subjected to Sephadex LH-20 CC using MeOH under isocratic conditions and was further separated on a semi-preparative C~18~ HPLC column with a gradient of MeOH/H~2~O (30:70--70:30) to produce (−)-vincapyridine A (**1**) (3 mg), (−)-vincapyridine B (**2**) (2 mg), and (−)-vincapyridine C (**3**) (1.2 mg).

(−)-vincapyridine A (**1**): C~13~H~17~NO~4~. white amorphous powder; $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$\left[ {\upalpha } \right]_{\text{D}}^{26}$$\end{document}$ −26.6 (*c* 0.07, MeOH); UV (MeOH) *λ* ~max~ (log ε): 203 (4.22), 220 (3.92), 270 (3.38); IR (KBr) *ν* ~max~ 3418, 2929, 1724, 1572, 1381, 1295, 1079 cm^−1^; ^1^H and ^13^C NMR data, see Table [1](#Tab1){ref-type="table"}; HRESIMS *m/z* 252.1222 \[M+H\]^+^ (calcd for C~13~H~18~NO~4~, 252.1230).

(−)-vincapyridine B (**2**): C~12~H~15~NO~4~. white amorphous powder; $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$\left[ {\upalpha } \right]_{\text{D}}^{26}$$\end{document}$ −190.0 (*c* 0.04, MeOH); UV (MeOH) *λ* ~max~ (log ε): 204 (4.44), 219 (4.13), 269 (3.57); IR (KBr) *ν* ~max~ 3419, 2926, 1724, 1606, 1383, 1042 cm^−1^; ^1^H and ^13^C NMR data, see Table [1](#Tab1){ref-type="table"}; HRESIMS *m*/*z* 238.1072 \[M+H\]^+^ (calcd for C~12~H~16~NO~4~, 238.1074).

(−)-vincapyridine C (**3**): C~11~H~15~NO~2~. white amorphous powder; $\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$\left[ {\upalpha } \right]_{\text{D}}^{26}$$\end{document}$ −359.8 (*c* 0.02, MeOH); UV (MeOH) *λ* ~max~ (log ε): 204 (3.35), 279 (2.64); IR (KBr) *ν* ~max~ 3425, 2926, 1720, 1623, 1383, 1035 cm^−1^; ^1^H and ^13^C NMR data, see Table [1](#Tab1){ref-type="table"}; HRESIMS *m/z* 194.1172 \[M+H\]^+^ (calcd for C~11~H~16~NO~2~, 194.1176).

Cytotoxicity Assay {#Sec7}
------------------

GITC-3^\#^ and GITC-18^\#^ (glioma initiating cell lines) were established previously in Kunming Institute of Zoology from three different human glioblastoma multiform samples. These cell lines were cultured in serum-free medium supplemented with 1XB27 (Life 12587-010), 50 ng/mL EGF (PeproTech AF-100-15), and bFGF (PeproTech AF-100-18B). GITCs were cultured in laminin (Gibco 1725712) pre-mdish. The cells could adhere and normally grow without differentiation. Culture dishes were pre-coated with laminin for 4-6 h at 10 mg/mL concentration. The T98G, U-87MG, and A549 cell lines were purchased from the American Type Culture Collection (ATCC), the cells were cultured in DMEM basic medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified incubator at 37 °C and an atmosphere of 5% CO~2~. Cells were digested with TryplE express (Gibco 12604-021) for 3--5 min at 37 °C in cell incubator and centrifuged at 1000 rpm/min for 3 min.

Cell viability analysis was performed by MTS \[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, Promega ^\#^G3581\] assay \[[@CR20], [@CR21]\]. The cells were digested and seeded on a 96-well plate with 20000 cells/well. Each tumor cell line was exposed to the test compound dissolved in DMSO at concentrations of 20 μg/mL and kept in cell incubator for 72 h. MTS reagent was diluted 1:5 with fresh medium and mixed well. The old medium was removed and subsequently the fresh medium was added with 100 μL/well. The cells were incubated for 1 h. Absorbance was measured by Hybrid Reader (BioTek Synergy H1) at 490 nm. The cell viability was evaluated by percentage compared with DMSO as a control group.

Supplementary Information {#Sec8}
=========================

1D and 2D NMR spectra, HRESIMS, and UV spectra of compounds **1**--**3** are available as Supplementary Information.
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